Table 1.

Clinical trials evaluating emavusertib in non-hodgkin lymphomas.

Clinical Trials.gov Identifier	Diseases Evaluated	Median Age, range	Median # of Prior Treatments, range	Any Grade Treatment Related Adverse Events	≥Grade 3 Treatment Related Adverse Events	Response	RP2D
NCT03328078	Phase 1a (Emavusertib monotherapy) DLBCL (n=14) MCL (n=2) MZL (n=2) WM (n=3) Transformed DLBCL (n=1) LPL (n=2) FL (n=6)	68.5 (50-87)	4 (1-8)	Fatigue (36%), Nausea (27%), Neutrophil count decreased (23%), Dizziness (18%), Hypercalcemia (18%), Hypophosphatemia (18%), Vomiting (18%).	Rhabdomyolysis (25%; n=8) of patients treated with 400mg BID	Eight of 28 evaluable patients experienced overall tumor burden decreases of ≥20% from baseline	300mg BID of Emavusertib
	Part 2a (Emavusertib + Ibrutinib 420mg or 560mg) DLBCL (n=2) CLL(n=2) MCL (n=2) MZL (n=3) WM (n=2) PCNSL(n=2)	66 (56-92)	3 (1-8)	NR	NR	ORR=44.4% (n=4/9) CR=2 (PCNSL and MCL) PR=2 (MCL and CLL) 5=SD	200mg BID of Emavusertib combined with Ibrutinib 420 or 560mg

DLBCL, diffuse large B cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; WM, Waldenstrom macroglobulinemia; LPL, lymphoplasmacytic lymphoma; FL, follicular lymphoma; CLL, chronic lymphocytic leukemia; PCNSL, primary CNS lymphoma; NR, not reported, ORR, overall response rate; CR; complete response; PR; partial response; SD, stable disease; RP2D, recommended phase II dose.

#, Number.